Atenolol and Timolol

Stephan Rössner; Leif Weiner; Anders Westerlund; Joel Zonszein; Peter Baylor; D. S. Lawrence; J. N. Sahay; S. S. Chatterjee; George T. Griffing; Christopher E. Coakley; Simmons Lessell; James C. Melby; S. Vožeh; William H. Frishman

doi:10.1056/NEJM198211183072116

Atenolol and Timolol

Stephan Rössner, Leif Weiner, Anders Westerlund, Joel Zonszein, Peter Baylor, D. S. Lawrence, J. N. Sahay, S. S. Chatterjee, George T. Griffing, Christopher E. Coakley, Simmons Lessell, James C. Melby, S. Vožeh, William H. Frishman

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Abstract

To the Editor: In a recent review of two β-blockers released for clinical use in the United States (June 17 issue) Frishman discusses the use of atenolol in treating hypertension.¹ One side effect not mentioned in the review is the induction of lipoprotein abnormalities during β-blockade. The general pattern in most studies seems to be an increase in the concentration of very-low-density lipoproteins and a decrease in the concentration of high-density lipoproteins during β-blockade.² Hyperlipoproteinemia is common in patients with hypertension, and an incidence of up to 40 per cent — twice as high as in controls — has.

Original language	English (US)
Pages (from-to)	1343-1346
Number of pages	4
Journal	New England Journal of Medicine
Volume	307
Issue number	21
DOIs	https://doi.org/10.1056/NEJM198211183072116
State	Published - Nov 18 1982
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM198211183072116

Cite this

@article{4f7f783202a54e56be72e31f5a0fdc14,

title = "Atenolol and Timolol",

abstract = "To the Editor: In a recent review of two β-blockers released for clinical use in the United States (June 17 issue) Frishman discusses the use of atenolol in treating hypertension.1 One side effect not mentioned in the review is the induction of lipoprotein abnormalities during β-blockade. The general pattern in most studies seems to be an increase in the concentration of very-low-density lipoproteins and a decrease in the concentration of high-density lipoproteins during β-blockade.2 Hyperlipoproteinemia is common in patients with hypertension, and an incidence of up to 40 per cent — twice as high as in controls — has.",

author = "Stephan R{\"o}ssner and Leif Weiner and Anders Westerlund and Joel Zonszein and Peter Baylor and Lawrence, {D. S.} and Sahay, {J. N.} and Chatterjee, {S. S.} and Griffing, {George T.} and Coakley, {Christopher E.} and Simmons Lessell and Melby, {James C.} and S. Vo{\v z}eh and Frishman, {William H.}",

year = "1982",

month = nov,

day = "18",

doi = "10.1056/NEJM198211183072116",

language = "English (US)",

volume = "307",

pages = "1343--1346",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "21",

}

TY - JOUR

T1 - Atenolol and Timolol

AU - Rössner, Stephan

AU - Weiner, Leif

AU - Westerlund, Anders

AU - Zonszein, Joel

AU - Baylor, Peter

AU - Lawrence, D. S.

AU - Sahay, J. N.

AU - Chatterjee, S. S.

AU - Griffing, George T.

AU - Coakley, Christopher E.

AU - Lessell, Simmons

AU - Melby, James C.

AU - Vožeh, S.

AU - Frishman, William H.

PY - 1982/11/18

Y1 - 1982/11/18

N2 - To the Editor: In a recent review of two β-blockers released for clinical use in the United States (June 17 issue) Frishman discusses the use of atenolol in treating hypertension.1 One side effect not mentioned in the review is the induction of lipoprotein abnormalities during β-blockade. The general pattern in most studies seems to be an increase in the concentration of very-low-density lipoproteins and a decrease in the concentration of high-density lipoproteins during β-blockade.2 Hyperlipoproteinemia is common in patients with hypertension, and an incidence of up to 40 per cent — twice as high as in controls — has.

AB - To the Editor: In a recent review of two β-blockers released for clinical use in the United States (June 17 issue) Frishman discusses the use of atenolol in treating hypertension.1 One side effect not mentioned in the review is the induction of lipoprotein abnormalities during β-blockade. The general pattern in most studies seems to be an increase in the concentration of very-low-density lipoproteins and a decrease in the concentration of high-density lipoproteins during β-blockade.2 Hyperlipoproteinemia is common in patients with hypertension, and an incidence of up to 40 per cent — twice as high as in controls — has.

UR - http://www.scopus.com/inward/record.url?scp=0019939852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019939852&partnerID=8YFLogxK

U2 - 10.1056/NEJM198211183072116

DO - 10.1056/NEJM198211183072116

M3 - Letter

C2 - 6752713

AN - SCOPUS:0019939852

SN - 0028-4793

VL - 307

SP - 1343

EP - 1346

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 21

ER -

Atenolol and Timolol

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this